von Bahr C, Wiesel F A, Movin G, Eneroth P, Jansson P, Nilsson L, Ogenstad S
Clinical Research, Astra Research Centre AB, Södertälje, Sweden.
Psychopharmacology (Berl). 1991;103(4):443-8. doi: 10.1007/BF02244242.
Six female and six male healthy volunteers received 100 mg remoxipride, 200 mg sulpiride and placebo as single oral doses in a double blind trial with a randomized crossover design. The main objective was to compare the effect of the two drugs on serum prolactin levels, but effects on other hormones were also investigated. Remoxipride and sulpiride increased the serum levels of prolactin to similar peak levels. This effect was larger in female than in male subjects. Sulpiride increased prolactin levels at much lower plasma concentrations than remoxipride, and sulpiride's effect on prolactin lasted for considerably longer than remoxipride's. No consistent effects on serum levels of LH, FSH, GH, oestradiol, progesterone, testosterone or cortisol could be detected after remoxipride and sulpiride compared to placebo. No drug-related effects on plasma homovanillic acid (HVA) were found.
在一项采用随机交叉设计的双盲试验中,6名女性和6名男性健康志愿者单次口服100毫克瑞莫必利、200毫克舒必利和安慰剂。主要目的是比较这两种药物对血清催乳素水平的影响,但也研究了对其他激素的影响。瑞莫必利和舒必利将血清催乳素水平升高至相似的峰值水平。这种效应在女性中比在男性中更明显。舒必利在比瑞莫必利低得多的血浆浓度下就能升高催乳素水平,且舒必利对催乳素的作用持续时间比瑞莫必利长得多。与安慰剂相比,服用瑞莫必利和舒必利后,未检测到对血清促黄体生成素、促卵泡生成素、生长激素、雌二醇、孕酮、睾酮或皮质醇水平有一致的影响。未发现与药物相关的对血浆高香草酸(HVA)的影响。